Drug intelligence / Profile preview

FCN-539

Development stage: Preclinical
Lead developer: Fochon Biosciences
Modality: Small Molecules

Overview

FCN-539 is a small molecule inhibitor of B-cell lymphoma 2 (BCL-2) currently under development by Chongqing Fochon Pharmaceutical. BCL-2 is a key anti-apoptotic protein that plays a critical role in the survival of various cancer cells, particularly in hematologic malignancies like lymphoma, by preventing programmed cell death. By selectively binding to and inhibiting BCL-2, FCN-539 triggers the apoptotic process in malignant cells. The drug is currently in the IND-enabling phase, targeting lymphoma as its primary indication.

Beyond the preview

Go deeper on FCN-539.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FCN-539.

Explore the full profile